PREVALENCE OF 2ND-GENERATION ANTIBODY TO HEPATITIS-C VIRUS AMONG VOLUNTARY BLOOD-DONORS IN OSAKA, JAPAN

被引：38

作者：

TANAKA, H

HIYAMA, T

TSUKUMA, H

OKUBO, Y

YAMANO, H

KITADA, A

FUJIMOTO, I

机构：

[1] Department of Field Research, Center for Adult Diseases, Osaka, 573, Osaka, 1-3-3 Nakamichi, Higashinari-ku

[2] Osaka Red Cross Blood Center, Osaka

来源：

CANCER CAUSES & CONTROL | 1994年 / 5卷 / 05期

关键词：

BLOOD DONORS; HEPATITIS-B VIRUS; HEPATITIS-C VIRUS; HEPATOCELLULAR CARCINOMA; JAPAN;

D O I：

10.1007/BF01694754

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To clarify the demographic characteristics of the prevalence of hepatitis C virus (HCV) infection in Osaka, Japan, where hepatocellular carcinoma is common, we investigated the screening data of antibody to HCV (anti-HCV, DAINABOTHCV PHA, second generation assay) in 197,600 voluntary blood donors residing in Osaka. The study found that age-standardized prevalence of anti-HCV was significantly higher than that of HBsAg (2.25 cf 0.86 percent among males, P < 0.001;2.17 cf 0.55 percent among females, P < 0.001. It was much higher in the blood donors aged 55-64 years than in those aged 16-54 years (8.49 cf 1.32 percent among males, P < 10(-5); 7.26 cf 1.42 percent among females, P < 10(-5)). The prevalence of anti-HCV among males was significantly higher than that of females in the younger (25-34 years) generations (1.02 to 1.49 percent cf 0.71 to 1.13 percent, P < 0.05). A similar tendency was observed in the prevalence of high-titer (greater-than-or-equal-to 2(12)) anti-HCV. The number of coinfection (both HBsAg and anti-HCV seropositive) was very small, and it was not statistically different from the expected number.

引用

页码：409 / 413

页数：5

共 27 条

[1]

DM, CS, SL, Cancer Incidence in Five Continents. Volume VI, (1992)

[2]

Annual Report of Osaka Cancer Registry No. 50, (1991)

[3]

Tanaka H., Hiyama T., Okubo Y., Kitada A., Fujimoto I., Primary liver cancer incidence-rates related to hepatitis-C virus infection: a correlational study in Osaka, Japan, Cancer Causes Control, 5, pp. 61-5, (1994)

[4]

Iino S., Koike K., Yasuda K., Et al., Second-generation assay for antibody to hepatitis C virus by passive haemagglutination (in Japanese), Prog Med, 7, pp. 1911-21, (1991)

[5]

Watanabe J., Matsumoto C., Fujimura K., Et al., Predictive value of screening tests for persistent hepatitis C virus infection evidenced by viremia, Vox Sang, 65, pp. 199-203, (1993)

[6]

Esteban J.I., Esteban R., Viladomiu L., Et al., Hepatitis C virus antibodies among risk groups in Spain, Lancet, 2, pp. 294-6, (1989)

[7]

Janot C., Courouce A.M., Maniez M., Antibodies to hepatitis C virus in French blood donors, Lancet, 2, pp. 796-7, (1989)

[8]

Kyhn P., Seidl S., Stangel W., Beyer J., Sibrowski W., Flik J., Antibody to hepatitis C virus in German blood donors, Lancet, 2, (1989)

[9]

Sirchia G., Almini D., Bellobuobo A., Et al., Prevalence of hepatitis C virus antibodies in Italian blood donors, Vox Sang, 59, pp. 26-9, (1990)

[10]

Watanabe J., Minegishi K., Mitsumori T., Et al., Prevalence of anti-HCV antibody in blood donors in the Tokyo Area, Vox Sang, 59, pp. 86-8, (1990)

← 1 2 3 →